|
1
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hainsworth JD and Greco FA: Treatment of
patients with cancer of an unknown primary site. N Engl J Med.
329:257–263. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris GJ, Greco FA, Hainsworth JD, et al:
Cancer of unknown primary site. Semin Oncol. 37:71–79. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kendall AR, Senay BA and Coll ME:
Spontaneous subcapsular renal hematoma: diagnosis and management. J
Urol. 139:246–250. 1988.PubMed/NCBI
|
|
5
|
McDougal WS, Kursh ED and Persky L:
Spontaneous rupture of the kidney with perirenal hematoma. J Urol.
114:181–184. 1975.PubMed/NCBI
|
|
6
|
Demos TC, Schiffer MS and Reynes CJ:
Metastatic leiomyosarcoma of the kidney with spontaneous perirenal
hemorrhage. Diagn Imaging Clin Med. 53:87–90. 1984.PubMed/NCBI
|
|
7
|
Hainsworth JD and Greco A: Neoplasms of
unknown primary site. Holland-Frei Cancer Medicine. Bast RC Jr,
Kufe DW, Pollock RE, et al: 5th edition. BC Decker; Hamilton, ON,
Canada: pp. 2114–2124. 2000
|
|
8
|
Golfinopoulos V, Pentheroudakis G, Salanti
G, et al: Comparative survival with diverse chemotherapy regimens
for cancer of unknown primary site: multiple-treatments
meta-analysis. Cancer Treat Rev. 35:570–573. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greco FA, Erland JB, Morrissey LH, et al:
Carcinoma of unknown primary site: phase II trials with docetaxel
plus cisplatin or carboplatin. Ann Oncol. 11:211–215. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greco FA, Burris HA III, Litchy S, et al:
Gemcitabine, carboplatin and paclitaxel for patients with carcinoma
of unknown primary site: a Minnie Pearl Cancer Research Network
study. J Clin Oncol. 15:1651–1656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Rayes BF, Shields AF, Zalupski M, et
al: A phase II study of carboplatin and paclitaxel in
adenocarcinoma of unknown primary. Am J Clin Oncol. 28:152–156.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Briasoulis E, Kalofonos H, Bafaloukos D,
et al: Carboplatin plus paclitaxel in unknown primary carcinoma: a
phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol.
18:3101–3107. 2000.PubMed/NCBI
|
|
13
|
Hainsworth JD, Spigel DR, Clark BL, et al:
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in
the first-line treatment of patients with carcinoma of unknown
primary site: a randomized, phase III Sarah Cannon Oncology
Research Consortium Trial. Cancer J. 16:70–75. 2010. View Article : Google Scholar
|
|
14
|
Grant R, Naylor B, Greenberg HS and Junck
L: Clinical outcome in aggressively treated meningeal
carcinomatosis. Arch Neurol. 51:457–461. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jayson GC and Howell A: Carcinomatous
meningitis in solid tumours. Ann Oncol. 7:773–786. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pavlidis N, Briassoulis E, Bai M, et al:
Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma
of unknown primary origin. Anticancer Res. 15:2563–2567.
1995.PubMed/NCBI
|
|
17
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
18
|
Massard C, Voigt JJ, Laplanche A, et al:
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu and
c-Kit tyrosine kinases potential targets for therapy? Br J Cancer.
97:857–861. 2007.PubMed/NCBI
|
|
19
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hainsworth JD, Spigel DR, Farley C, et al;
Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab
and erlotinib in carcinomas of unknown primary site: the Minnie
Pearl Cancer Research Network. J Clin Oncol. 25:1747–1752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
